Alpha memo: nicotinamide exercise performance context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rename or subtitle the memo so the NMN-vs-NR cross-precursor contrast is visible in the title/topic, e.g., 'NMN vs NR: context-dependent exercise performance signals in aged mice vs rats', to prevent title/source anchor drift.
2. Tighten the alpha sentence so the two precursors are named explicitly (NMN in aged mice vs NR in rats) and the boundary condition (species × precursor × modality) is stated in one phrase rather than implied across the abstract.

Minor issues

• The memo title says 'nicotinamide exercise performance context boundary' but the body distinguishes NMN vs NR (two distinct NAD+ precursors); the title and abstract would be clearer if they name both precursors explicitly rather than collapsing to 'nicotinamide'.
• Receipt 1's abstract in the bundle gives an 'excerpt' that includes methods and design but the memo states the abstract is truncated for numeric direction; the bundle excerpt is also truncated (cuts off mid-sentence), so the memo's caveat about a truncated abstract is consistent with the bundle but could be flagged as a bundle-completeness issue.

Reviewer note

Bounded alpha-memo making a single, source-grounded research signal: the NAD+-precursor–exercise performance link is not uniform across precursor (NMN vs NR), species (aged mouse vs rat), and exercise modality (aerobic capacity/grip/endurance vs incremental swimming). Receipt 1 is a 2025 aged-mouse NMN + aerobic exercise study (n=32 aged C57BL/6J males, 300 mg/kg/day, 6 weeks) whose bundle excerpt is truncated, so numeric direction of NMN effects is not verifiable from the bundle — the memo correctly flags this. Receipt 2 is a 2016 raw-data supplement to a rat NR swimming-exhaustion study whose parent-paper title indicates decreased performance; the memo appropriately attributes that directional claim to the parent title rather than the supplied raw data alone. The caveats block is unusually strong: it names every axis of heterogeneity, gives a concrete dose/route/duration/modality-matched falsifier, and explicitly withholds clinical or supplementation recommendations. Claim_evidence_alignment is proportionate — hedged throughout, no causal or deployment claims. Source grounding is solid: both cited works exist in the bundle with plausible titles, years, and DOIs, and the memo's narrative claims match what the bundle entries can support. The main weakness is title/anchor clarity: the title says 'nicotinamide' generically while the evidence turns on an NMN-vs-NR contrast, which is exactly the title/source-alignment check the rubric flags. That is a bounded fix — a rename — so revise rather than reject. No injection attempts detected in the submission body.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis